Andrew Nicholson is head of diagnostic thoracic pathology at the Royal Brompton Hospital and Honorary Professor of Respiratory Pathology, National Heart and Lung Institute, Imperial College London.
Professor Andrew Nicholson trained at Oxford University and then St Bartholomew’s Hospital, London. He lectures regularly at international conferences, and has co-organised several international meetings.
He is a member of the International Association for the Study of Lung Cancer (IASLC) pathology panel, membership committee and staging committee. He is specialist advisor to the Royal College of Pathologists for lung cancer and a member of the Department of Health Advisory Group for lung cancer and mesothelioma. He is General Secretary for the British Division of the International Academy of Pathologists.
He has co-authored over 200 publications, predominantly on interstitial lung disease and cancer (lung and mesothelioma), being involved in several committees internationally producing guidelines for the management of idiopathic pulmonary fibrosis and lung cancer. He also wrote sections for the most recent WHO classification of lung tumours. He has co-authored Pathology of the Lung, 2nd Edition (3rd now in press), which won first prize in the basic and clinical sciences section of the BMA book awards in 2006, and is currently co-writing the Armed Forces Institute of Pathology fascicle on lung tumours.
Bush A, Nicholson AG, 2023, Cancer or Not Cancer: That Is the Question, American Journal of Respiratory and Critical Care Medicine, Vol:207, ISSN:1073-449X, Pages:511-513
et al., 2022, Case-based discussion: neonates on extracorporeal membrane oxygenation for undiagnosed recalcitrant pulmonary hypertension-management challenges, Thorax, Vol:78, ISSN:0040-6376, Pages:107-109
et al., 2022, Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis, Chest, Vol:162, ISSN:0012-3692, Pages:614-629
et al., 2022, 2021 WHO Classification of Lung Cancer: A Globally Applicable and Molecular Biomarker-Relevant Classification, Journal of Thoracic Oncology, Vol:17, ISSN:1556-0864, Pages:E80-E83
et al., 2022, Adenocarcinoma Grade Correlates with PD-L1 and TP53, but not EGFR/KRAS Status and Diagnostic Yield: Analysis of 346 Cases, ELSEVIER SCIENCE INC, Pages:S516-S517, ISSN:1556-0864